MentionFox
Home › funding signals › Evia Bio, Inc.
Form D · on the record

Evia Bio — $5.45M Form D filing, September 2026

Evia Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-28.

Evia Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 28, 2026. The filing reports $5.45M sold. Its industry group is Biotechnology. It names Jeffrey Allen (Executive Officer, Director), Marc Centrella (Director), Scott Fisher (Director) (SEC Form D, September 28, 2026).

Sell to companies like Evia Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Evia Bio, Inc. raised on Sep 28. 137 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Linework USA INC.$1.2BAI and software
Linework USA INC.$326MAI and software
Pathos AI, Inc.$238MBiotech
Galvanize Therapeutics, Inc.$136MBiotech
Tractian Inc.$106MAI and software
Check one company free All companies that raised this week

3 more Biotechnology raises in Minnesota within 90 days ↓

Selling to Evia Bio, Inc.? See who runs it and how to reach them, plus this week's 162 other newly funded companies.

Is this your company?

Key facts

Run the free check on Evia Bio, Inc. →

Evia Bio, Inc.

New Form D on file · 2026-09-28 · the record

$5.45M
raise on the record
D
filing
19
investors in
MINNESOTA
based
Open the record →

What the record says

FilingForm D
Filed2026-09-28
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedMinneapolis, MINNESOTA
CIK1954759
Accession0001954759-26-000004

Pitching, partnering or investing alongside them? See who really runs and owns Evia Bio, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Evia Bio, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Minnesota, filed within 90 days of this one, largest first.

What do you want to do with Evia Bio, Inc.?

Get the full cited report on Evia Bio, Inc.

What the filing shows about Evia Bio, Inc.

  • The filing reports $95K of the proceeds going to the company's own executives, directors or promoters.
  • 19 investors had already put money in when it filed.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Evia Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look Evia Bio, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Evia Bio, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives Evia Bio, Inc.'s address as 2001 6th Street Se, Room 2-434 Bench 33, Minneapolis, MN 55455.

What the filing says

  • Offered: $5,453,532. Sold: $5,453,532. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 19 had already invested. (filing)
  • Date of first sale: September 14, 2026. (filing)
  • Types of securities: Equity. (filing)
  • Item 16, payments to executive officers, directors or promoters: $95,192 of the proceeds is used or proposed to be used for such payments. The filing explains: “Accrued consulting fees.” (filing)
  • Securities that converted: the filing says “In addition to the shares sold for cash in the offering $3,453,532.33 of Convertible Promissory Notes converted into shares of the Issuer's Preferred Stock.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Evia Bio, Inc. See pricing

Is Evia Bio, Inc. a real, registered company?

Evia Bio, Inc. is a registered filer with the SEC (CIK 1954759) and has filed since 2026-09-28. 1 filing is on record, the latest on 2026-09-28.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Evia Bio, Inc.?

Evia Bio, Inc.'s Form D of 2026-09-28 names Jeffrey Allen, Marc Centrella, Scott Fisher and 2 more as its officers, directors or promoters.

How much has Evia Bio, Inc. raised?

Its new offerings report $5.45M sold across 1 offering, as its own filings state.

Biotechnology · by week
This raise, $5.45M, filed week of Sep 28

Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $5.45M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Evia Bio, Inc.?

What the filing shows about Evia Bio, Inc.

  • The filing reports $95K of the proceeds going to the company's own executives, directors or promoters.
  • 19 investors had already put money in when it filed.
  • The filing names 5 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Evia Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Evia Bio, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for Evia Bio, Inc.. With no account yet, you sign up free and land on the result.

On these startup lists

Biotech startups

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Evia Bio, Inc.: Raised $5.45M, Form D filed 2026-09-28
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/evia-bio-inc-form-d-000004
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Evia Bio raised $5.45M — SEC Form D filing, September 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/evia-bio-inc-form-d-000004